



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to:
MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA
22313-1450, on the date shown below.

Dated: 3/22/05

Signature: Crena Pacheco
(Crena Pacheco)

Docket No.: WIBL-P01-534
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Clark et al.

Application No.: 09/735273

Confirmation No.: 3583

Filed: December 11, 2000

Art Unit: 1634

For: METASTASIS GENES AND USES
THEREOF

Examiner: J. C. Switzer

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Supplemental Information Disclosure Statement is filed more than three months after the U.S. filing date, OR more than three months after the date of entry of the national stage of a PCT application, AND after the mailing date of the first Office Action on the merits, whichever occurs first, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)).

A copy of each reference on the PTO/SB/08 is attached.

In accordance with 37 CFR 1.97(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h),

the filing of this Supplemental Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Supplemental Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Please charge our Deposit Account No. 18-1945 in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. WIBL-P01-534. A duplicate copy of this paper is enclosed.

Dated: 3/22/05

Respectfully submitted,

By Lisa Treannie
Lisa Treannie

Registration No.: 41,368
ROPES & GRAY LLP
One International Place
Boston, Massachusetts 02110-2624
(617) 951-7000
(617) 951-7050 (Fax)
Attorneys/Agents For Applicant



PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
				Application Number	09/735273
				Filing Date	December 11, 2000
				First Named Inventor	Edwin A. Clark
				Art Unit	1634
				Examiner Name	J. C. Switzer
Sheet	1	of	2	Attorney Docket Number	WIBL-P01-534

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)			
					T ⁶

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
CA	AN, Z, et al, "A clinical nude mouse metastatic model for highly malignant human pancreatic cancer."; <i>Anticancer Res.</i> 1996 Mar-Apr; 16(2):627-31				
CB	AN, Z, et al, "Conversion of highly malignant colon cancer from an aggressive to a controlled disease by oral administration of a metalloprotease inhibitor."; <i>Clin Exp Metastasis</i> . 1997 Mar; 15(2):184-95				
CC	ANDERSON, ROBIN L.; "Peter MacCallum Cancer Institute, GenesImportant in Breast Cancer Metastasis"; National Cancer Institute; Abstract 5R01CA090291-02 (2001)				
CD	CHA, HEE-JAY, et al., "Role of Thymosin Beta4 in Tumor Metastasis and Angiogenesis," <i>Journal of the National Cancer Institute</i> , 95(22):1674-1680 (2003)				
CE	CHER, MICHAEL; "Wayne State University Prostate Cancer, Bone Metastasis, and Metalloproteinases; National Institute of Cancer; Abstract 5R01CA088028-03 (2000)				
CF	CHRISTENSEN, LISE, "The distribution of fibronectin, laminin and tetranectin in human breast cancer with special attention to the extracellular matrix," <i>APMIS Suppl.</i> 26(100):6-36 (1992)				
CG	FRANKE, F.E., et al., "Association between Fibronectin Expression and Prognosis in Ovarian Carcinoma," <i>Anticancer Research</i> , 23:4261-4267 (2003)				
CH	GOLDSTEIN, ALLAN L., "Thymosin Beta4: A New Molecular Target for Antitumor Strategies," <i>Journal of the National Cancer Institute</i> , 95(22):1646-1647 (2003)				
CI	IOACHIM, E., et al., "Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression," <i>European Journal of Cancer</i> , 38:2362-2370 (2002)				
CJ	LIU, CONG-RONG, et al., "Differential thymosin beta10 expression levels and actin filament organization in tumor cell lines with different metastatic potential," <i>Chinese Medical Journal</i> , 117(2):213-218 (2004)				
CK	MARGALIT, O., et al., "Overexpression of a set of genes, including WISP-1, common to pulmonary metastases of both mouse D122 Lewis lung carcinoma and B16-F10.9 melanoma cell lines," <i>British Journal of Cancer</i> , 89:314-319 (2003)				
CL	QUENTIN, THOMAS, et al., "Alteration of the Vascular Endothelial Growth Factor and Angiopoietins-1 and -2 Pathways in Transitional Cell Carcinomas of the Urinary Bladder				

Examiner Signature	Date Considered
--------------------	-----------------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete If Known	
				Application Number	09/735273
				Filing Date	December 11, 2000
				First Named Inventor	Edwin A. Clark
				Art Unit	1634
				Examiner Name	J. C. Switzer
Sheet	2	of	2	Attorney Docket Number	WIBL-P01-534

		Associated with Tumor Progression," Anticancer Research, 24:2745-2756 (2004)	
CM		RIDLEY, ANNE, "Molecular switches in metastasis," Nature, 406:466-467 (2000)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ** CITE NO.: Those document(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--